Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | PTPRF | P10586 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20370324 | 0.81 | ALDH1A1 (0.47) | CA1CA12CA9TDP1TSHR | |
| SCHEMBL20358397 | 0.78 | POLB (0.63) | SETD7TDP1KMT2APOLBHSD17B10 | |
| SCHEMBL26090324 | 0.78 | CA1 (0.48) | SETD7SLC6A3CA1CA2CA12 | |
| SCHEMBL2944680 | 0.77 | ALDH1A1 (0.48) | SLC6A3CA1CA2CA12CA9 | |
| SCHEMBL20370328 | 0.77 | SMN1; SMN2 (0.36) | SLC6A3PTPN1ALDH1A1MAPT | |
| SCHEMBL2950950 | 0.75 | ALDH1A1 (0.47) | SLC6A3CA1CA2CA12CA9 | |
| SCHEMBL2949298 | 0.75 | ALDH1A1 (0.47) | SLC6A3CA1CA2CA12CA9 | |
| SCHEMBL2949295 | 0.75 | ALDH1A1 (0.47) | SLC6A3CA1CA2CA12CA9 | |
| SCHEMBL19387238 | 0.75 | CA1 (0.70) | SETD7CA1CA2CA12CA9 | |
| Cyclohexane SCHEMBL1133519 | 0.75 | CA1 (0.70) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345652-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS (CA) | 2022-05-31 | — | — | US | disclosed |
| US-20200148623-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2020-05-14 | — | — | US | disclosed |
| US-10556853-B2 | Anticonvulsant compounds | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2020-02-11 | — | — | US | disclosed |
| WO-2018129609-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2018-07-19 | — | — | WO | disclosed |
| US-20180194715-A1 | ANTICONVULSANT COMPOUNDS | OWEN-BARRY PHARMACEUTICALS INC. (CA) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194715-A1 | ANTICONVULSANT COMPOUNDS | GABRE, CACNA1B, GRIK5 | SETD7 4560/4885SLC6A3 1031/4885CA1 102/4885 |
| US-20200148623-A1 | ANTICONVULSANT COMPOUNDS | GABRE, CACNA1B, GRIK5 | SETD7 4560/4885SLC6A3 1031/4885CA1 102/4885 |
| US-11345652-B2 | Anticonvulsant compounds | GABRE, CACNA1B, GRIK5 | SETD7 4560/4885SLC6A3 1031/4885CA1 102/4885 |
| US-10556853-B2 | Anticonvulsant compounds | GABRE, CACNA1B, GRIK5 | SETD7 4560/4885SLC6A3 1031/4885CA1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.